Navigation Links
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
Date:7/14/2008

MOUNTAIN VIEW, Calif., July 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine.

MAP0004 is orally inhaled and self-administered at home using MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In the company's prior Phase 2 efficacy study, MAP0004 provided pain relief in as fast as 10 minutes, with relief sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia, the other key measurements in treating migraine.

This randomized, double-blind, placebo-controlled Phase 3 trial is designed to evaluate the efficacy and safety of MAP0004 in treating acute migraine. The primary efficacy endpoints will be pain relief, and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. MAP will also evaluate earliest onset of pain relief and sustained relief to 24 and 48 hours. The multi-center efficacy trial will include approximately 850 patients, who will also be followed for 12 months in an open-label study to confirm long-term safety.

"We believe that MAP0004 has the potential to be a first-line therapy for migraine patients," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Based on our initial clinical studies, we believe that MAP0004 offers an alternative to triptans that may provide patients with the benefits of rapid onset and long-lasting pain relief, in an easy-to-use, non-invasive, at-home therapy. In our Phase 2 trials, MAP0004 was well tolerated with no effect on pulmonary function, including in asthmatic subjects."

The therapeutic agent
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... BEVERLY HILLS, Calif. , Jan. 14, 2014 The Brandeis ... Los Angeles a premier and affordable laser tattoo ... treatment special. Dr. Brandeis, focus is in providing high quality cosmetic ... to all patients. " Southern California ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... the Horizon 2" Special Session, ROCKVILLE, Md., ... a clinical-stage pharmaceutical company developing,therapeutics for the treatment ... present preclinical data for its product candidates,ENMD-2076, MKC-1, ... EntreMed,scientists and collaborators during the American Association for ...
... to improve ... management of risk for infection, BOSTON, April 10 ... lung transplantation at the,University of Pittsburgh Medical Center (UPMC) has ... with,microbial analysis of bronchoalveolar (BAL) fluids in immunosuppressed,patients, can help ...
Cached Medicine Technology:EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting 2EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting 3Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients 2Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients 3
(Date:4/23/2014)... testosterone falls below normal levels are more likely to ... heart disease and type 2 diabetes. A new simple ... testing and possible treatment is described in an article ... publication from Mary Ann Liebert, Inc., publishers. The article ... Health website at http://www.liebertpub.com/jmh . ...
(Date:4/23/2014)... accessible detection methods that can rapidly screen a ... single cell inside that population has been seriously ... , In the Royal Society of Chemistry journal ... he and his coworkers have developed a novel ... protein ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
(Date:4/23/2014)... health benefits of probiotics, antioxidants and other nutritional compounds, ... chemical industry is getting in on the action. But ... so the industry is responding with clinical research to ... in Chemical & Engineering News (C&EN), the ... Melody M. Bomgardner, a senior editor at C&EN, writes ...
(Date:4/23/2014)... country as wealthy as the United States, it may come ... have access to adequate food due to lack of money ... Recent research at the University of Illinois using data from ... the seniors who are dealing with hunger are also facing ... percent of Americans over age 60 faced the threat of ...
(Date:4/23/2014)... A team of scientists led by a researcher from ... the National University of Singapore has identified the cancer ... opens up the possibility of developing new drugs for ... cancers. , The research group, led by Dr Chan ... for the first time that a cancer-specific variant of ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... are at a greater risk of catching bird flu, as the ... ,A study on cats in areas where outbreaks have ... than thought. It raises the chilling prospect that the disease could ... human pandemic. And it shows that should bird flu ever break ...
... have patented a device, which is capable of the ... by various bacteria, notable amongst which are Salmonella, Campylobacter ... due to food poisoning, as well as of other ... the aim of extending the uses of the device ...
... Dengue fever is a viral infection transmitted through the ... patients //never knowing they have been infected. However, in ... tendency triggering the often-fatal Dengue Shock Syndrome. Because some ... the virus from the tropics back to their home ...
... rise in pneumonia, bronchitis and other acute respiratory infections in ... the United Nations health agency is sending antibiotics for thousands ... many more from catching the illnesses. ,“Early ... save lives,” UN spokesman Adrian Edwards told a press briefing ...
... diuretic drugs should not be recommended as a way to ... caused during pregnancy. It is characterized by high blood pressure, ... urine. The high blood pressure can affect the brain, kidneys, ... in the 1960s to women in order to avoid dangerously ...
... of researchers has constructed a model that predicts how ... by airliners. ,The study, "Modeling the Worldwide ... appears in the January issue of the journal PLoS ... the world's largest-scale epidemic simulation of its kind. ...
Cached Medicine News:Health News:Cat Owners at Risk of Bird Flu 2Health News:A Patented Device for Rapid Diagnosis of Diseases 2Health News:Europeans Developing First-Ever Dengue Fever Vaccine 2Health News:UN Sends Medicine to Afghanistan 2Health News:Avoid Diuretic Pills During Pregnancy 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 3
... microplate incubator is an extremely compact ... single microplate up to 50C. ... requiring higher temperatures up to 65C. ... low cost and high performance for ...
... The Solo microplate incubator is an ... incubating a single microplate up to ... incubates applications requiring higher temperatures up ... solution offering low cost and high ...
... The iEMS Incubator/Shaker HT ... Thus, the iEMS Incubator/Shaker HT ... as DNA hybridization and primer ... is available as a one-cabinet ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Medicine Products: